Management of High-Risk HPV on Pap Test Result
Risk-Based Management Framework
- The American Society for Colposcopy and Cervical Pathology (ASCCP) uses a risk-based approach that stratifies management based on the patient's risk of CIN 3, not just the test result itself 2, 3
Immediate Colposcopy Required
- Colposcopy is required for patients with HPV 16 or 18 positive results, regardless of cytology result, even if Pap test is normal 1, 4, 5
- The American College of Obstetricians and Gynecologists (ACOG) recommends colposcopy for patients with high-grade cytology, such as HSIL or ASC-H 2, 3, 4
- Colposcopy is always recommended for two consecutive HPV-positive tests, regardless of previous Pap results 1, 4
Deferred Colposcopy (1-Year Follow-Up)
- The ASCCP recommends repeat HPV testing with or without concurrent Pap test in 1 year for lower-risk scenarios, such as HPV positive (non-16/18) with normal or minimally abnormal cytology 2, 3, 4
- If cytology is abnormal or HPV test remains positive at 1-year follow-up, refer to colposcopy 2, 3
Post-Treatment Surveillance
- The American Cancer Society recommends post-treatment surveillance for at least 25 years after treatment for high-grade precancer (CIN 2/3), with initial testing at 6, 18, and 30 months using HPV test or cotest 1, 5
- Long-term surveillance should be performed every 3 years with HPV/cotest or annually with cytology alone 1, 5